Terapia com Células T CAR Biespecíficas CD19/CD22 para Linfoma de Grandes Células B Recorrente/Refratário
Terapia com Células T CAR Biespecíficas CD19/CD22 para Linfoma de Grandes Células B Recidivante/Refratário: Um Estudo Prospectivo, de Braço Único, Monocêntrico, de Fase 2
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Large B cell lymphoma (LBCL) is the most common aggressive subtype of non-Hodgkin lymphoma (NHL) in adults. While approximately 60% of patients can be cured with first-line therapy, a subset of patients experiences relapse or refractory disease (R/R). The prognosis for R/R LBCL patients is poor, with limited efficacy from traditional treatments such as autologous stem cell transplantation (ASCT) and novel targeted agents. Chimeric antigen receptor-T (CAR-T) cell therapy involves genetically engineering T cells to express chimeric antigen receptors (CARs) that target tumor-specific antigens, enabling precise elimination of tumor cells. CD19 is the most commonly targeted antigen in B-cell malignancies, however, antigen escape following CD19 CAR-T therapy can lead to disease relapse in some patients. Studies indicate that CD22 is widely expressed in B-cell malignancies and exhibits incomplete overlap with CD19 expression, suggesting that dual-target CAR-T therapy may more comprehensively eradicate tumor cells. Therefore, dual-target CAR-T therapy, particularly strategies targeting both CD19 and CD22, has emerged as a promising approach to overcome antigen escape and enhance therapeutic outcomes. In this prospective study, the investigators aimed to evaluate the efficacy and safety of CD19/CD22 bispecific CAR-T cell (CAR2219) therapy in patients with R/R LBCL.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Beijing Tongren Hospital, Capital Medical University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 14 years to 85 years, expected survival > 3 months;
- CD19 positive with or without CD22 positive Large B-cell lymphoma;
- relapsed or refractory disease;
- ECOG-PS score=0-2;
- Having at least one measurable lesion;
- Cardiac function: 1-2 levels;
- Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN;
- kidney: Cr≤1.25ULN;
- bone marrow: WBC ≥ 3.0×10e9/L, Hb ≥80 g/L, PLT ≥ 50×10e9/L;
- No serious allergic constitution;
- No other serious diseases that conflicts with the clinical program;
- No other cancer history;
- No serious mental disorder;
- Informed consent is signed by a subject or his lineal relation.
Exclusion Criteria:
- Pregnant or lactating women (female participants of reproductive potential must have a negative serum or urine pregnancy test);
- Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
- Active hepatitis B or hepatitis C infection;
- With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
- Participate in other clinical research in the past 4 weeks;
- Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: CD19/CD22 CAR-T group
Patients would receive autologous CAR-T cell therapy targeting both CD19 and CD22. The dosage for CD19/CD22 bispecific CAR-T cells was 2×10e6/kg. |
CD19/CD22-bispecific CAR-T cells were infused at the dosage of 2×10e6/kg |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
best overall response rate (ORR) as of 3 months post-CAR-T cells infusion
Prazo: From the day of CAR-T cells infusion to 3 months post-CAR-T cells infusion
|
Overall response rate means sum of complete response rate and partial response rate |
From the day of CAR-T cells infusion to 3 months post-CAR-T cells infusion
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Best Complete Response rate (CR) as of 3 months post-CAR-T cells infusion
Prazo: From the day of CAR-T cells infusion to 3 months post-CAR-T cells infusion
|
CR was defined as complete response evaluated using PET-CT scan |
From the day of CAR-T cells infusion to 3 months post-CAR-T cells infusion
|
|
Progression free survival (PFS)
Prazo: From the day of CAR-T cells infusion to 12 months post-CAR-T cells infusion
|
PFS was defined from the date of CAR-T infusion to the date fo confirmed disease progression or death of any reason |
From the day of CAR-T cells infusion to 12 months post-CAR-T cells infusion
|
|
overall survival (OS)
Prazo: From the day of CAR-T cells infusion to 12 months post-CAR-T cells infusion
|
OS was defined from the date of CAR-T infusion to the date fo death |
From the day of CAR-T cells infusion to 12 months post-CAR-T cells infusion
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Prazo: From the day of CAR-T cells infusion to 12 months post-CAR-T cells infusion
|
measured using CTCAE version 5.0 |
From the day of CAR-T cells infusion to 12 months post-CAR-T cells infusion
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Liang Wang, M.D., Beijing Tongren Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- TRhos-CART-02
- 2025ZD0544300 (Número de outro subsídio/financiamento: Noncommunicable Chronic Diseases-National Science and Technology Major Project)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .